Open AccessActual possibilities and perspectives of biological drugs in treatment of systemic vasculitides. III. Biological drugs in giant cell arteritis
Author(s) -
Dimo Dimov
Publication year - 2021
Publication title -
revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2738-831X
pISSN - 1310-0505
DOI - 10.35465/29.1.2020.pp8-20
Subject(s) - tocilizumab , giant cell arteritis , medicine , tolerability , vasculitis , immunology , intensive care medicine , pharmacology , disease , adverse effect
A review of the literary data about the hitherto exiting investigations on biological drugs (BDs) as an alternative of the corticosteroids (CSs) – the current basal therapy of giant cell arteritis (GCA) is presented. The TNF-alpha-inhibitors are already definitely discarded on the account of their inefficiency and inadequate tolerability. The favorable initial results of BDs against IL-1, CTLA4-iGg1 and especially IL-12/23 should receive a reliable assessment after completion of the additional large-scale investigations. Indisputably only the data on efficacy of tocilizumab (anti-IL-6) for induction and maintenance of GCA remission and its marked CS-saving effect are convincing. Reasonably, TCM received a permission for use as adjunctive therapy in the management of GCA.